Research Topics
Genomes and Genes
| Y YardenSummaryAffiliation: Weizmann Institute of Science Country: Israel Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapyAmi Citri
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
EMBO J 21:2407-17. 2002..Based upon a model for drug-induced degradation of ErbB-2, we propose a general strategy for selective destruction of oncoproteins by targeting their interaction with molecular chaperones...
p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapyYaara Zwang
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
EMBO J 25:4195-206. 2006..Hence, by preventing EGFR-mediated survival signaling, the internalization route we uncovered enhances the cytotoxic effect of drugs like cis-platinum, which may underlie interactions between chemotherapy and EGFR-targeting drugs...
The ERBB network: at last, cancer therapy meets systems biologyYosef Yarden
Department of Biological Regulation, Weizmann Institute of Science, 1 Hertzl Street, Candiotty Building, Room 312, Rehovot 76100, Israel
Nat Rev Cancer 12:553-63. 2012....
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGFGabi Tarcic
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
FASEB J 26:1582-92. 2012..In summary, EGR1 and the EGF-ERK-ERF axis emerge from our study as major drivers of growth factor-induced mammary cell migration...
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunitiesY Yarden
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
Eur J Cancer 37:S3-8. 2001....
Untangling the ErbB signalling networkY Yarden
Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
Nat Rev Mol Cell Biol 2:127-37. 2001..Likewise, small-molecule enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clinical testing. What can this pathway teach us about translating basic science into clinical use?..
The biological framework: translational research from bench to clinicYosef Yarden
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncologist 16:23-9. 2011..Complex growth factor signaling networks and novel methods to shut down these networks are described within a framework of engineering and mathematical concepts...
Biology of HER2 and its importance in breast cancerY Yarden
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncology 61:1-13. 2001..The reported clinical therapeutic efficacy of anti-HER2 monoclonal antibodies in breast cancer highlights the importance of understanding the biology of HER2...
The biological framework: translational research from bench to clinicYosef Yarden
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncologist 15:1-7. 2010..Complex growth factor signaling networks and novel methods to shut down these networks are described within a framework of engineering and mathematical concepts...
Molecular approach to breast cancer treatmentYosef Yarden
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Semin Oncol 31:6-13. 2004..Improved molecular characterization and greater understanding of tumorigenesis will enable more individualized treatment...
An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4X Chen
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
J Biol Chem 271:7620-9. 1996..These results suggest that homodimers of ErbB-4 are biologically active, but heterodimerization of the kinase-defective ErbB-3, probably with ErbB-2, is essential for transmission of NDF signals through ErbB-3...
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factorE Tzahar
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Mol Cell Biol 16:5276-87. 1996..The observed superior ability of ErbB-2 to form heterodimers, in conjunction with its uniquely high basal tyrosine kinase activity, may explain why ErbB-2 overexpression is associated with poor prognosis...
Bivalence of EGF-like ligands drives the ErbB signaling networkE Tzahar
Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel
EMBO J 16:4938-50. 1997..Thus, ligand bivalence enables signal diversification through selective recruitment of homo- and heterodimers of ErbB receptors, and it may explain oncogenicity of erbB-2/HER2...
c-Cbl is a suppressor of the neu oncogeneG Levkowitz
Departments of Biological Regulation and Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
J Biol Chem 275:35532-9. 2000..Our results implicate c-Cbl in negative regulation of Neu and offer a potential target for treatment of HER2/ErbB-2-positive human malignancies...
The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routingH Waterman
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
EMBO J 18:3348-58. 1999....
The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transductionJ M Blechman
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Cell 80:103-13. 1995..These results identify an intrinsic receptor dimerization site and suggest that similar sites may exist in other receptors...
Structure-function analyses of the kit receptor for the steel factorJ M Blechman
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Stem Cells 11:12-21. 1993..Further experiments suggested that a putative dimerization site is distinct from the binding cleft and may be located on the fourth Ig-like domain...
Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factorJ M Blechman
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
J Biol Chem 268:4399-406. 1993..Hence, the binding site of SCF probably includes Ig-like domains 1 and 2, but structural determinants distal to this portion may also participate in ligand recognition...
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1G Levkowitz
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Mol Cell 4:1029-40. 1999..Our study identifies Cbl proteins as components of the ubiquitin ligation machinery and implies that they similarly suppress many other signaling pathways...
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasisM Lindzen
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Oncogene 31:3505-15. 2012..Taken together, the activities displayed by TRAP-Fc reinforce critical roles of EGF-like growth factors in tumor progression, and they warrant further tests of TRAP-Fc in preclinical models...
ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytesM Marikovsky
Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Oncogene 10:1403-11. 1995..We conclude that different isoforms of NDF induce distinct growth regulatory effects on cultured keratinocytes, through direct interaction with ErbB-3...
The murine flg gene encodes a receptor for fibroblast growth factorA Safran
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Oncogene 5:635-43. 1990..The latter exhibited progressive cranio-caudal concentration into the intervertebral discs. Taken together, these results strongly suggest that the flg gene encodes a receptor for fibroblast growth factor(s)...
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexesM Shelly
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
J Biol Chem 273:10496-505. 1998..This remarkable discrepancy between binding affinity and bioactivity is permitted by a mechanism that prevents receptor down-regulation, and results in a weak, but prolonged, state of receptor activation...
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gammaE Peles
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
EMBO J 10:2077-86. 1991..Based on the presented results we suggest that the mechanism of cellular transformation by the neu/HER2 receptor involves tyrosine phosphorylation and activation of PLC gamma...
Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21A Orr-Urtreger
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Proc Natl Acad Sci U S A 90:1867-71. 1993..In situ hybridization of a 3H-labeled probe to human metaphase spreads localized the NDF gene to the short arm of chromosome 8 at bands p12-p21...
Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinasesD Karunagaran
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
J Biol Chem 270:9982-90. 1995..This model of negative trans-regulation within the ErbB family is relevant to other subgroups of receptor tyrosine kinases and may have physiological implications...
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinationsR Pinkas-Kramarski
Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel
J Biol Chem 271:19029-32. 1996..These results imply that NDF isoforms differ in their ability to induce receptor heterodimers; whereas both types of isoforms signal through ErbB-3/ErbB-2 heterodimers, only beta isoforms are able to stabilize ErbB-3/ErbB-1 heterodimers...
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC R Pradeep
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Oncogene 31:3569-83. 2012..In conclusion, the integration of a three-dimensional cellular model and clinical data attributes progression of HER2-overexpressing lesions to EGF-like growth factors acting in the context of the tumor's microenvironment...
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progressionF Pareja
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Oncogene 31:4599-608. 2012..In conclusion, deubiquitination by Cezanne-1 curtails degradation of growth factor receptors, thereby promotes oncogenic growth signals...
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signalingK Shtiegman
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncogene 26:6968-78. 2007..Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation...
Developmental expression of c-kit, a proto-oncogene encoded by the W locusA Orr-Urtreger
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Development 109:911-23. 1990..Correlation between W phenotypes and c-kit expression, as well as the regulation of the complex and multiple expression of polypeptide growth factors and receptors, is discussed...
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinaseD Harari
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncogene 18:2681-9. 1999..The primary structure and the pattern of expression of NRG-4, together with the strict specificity of this growth factor to ErbB-4, suggest a physiological role distinct from that of the known ErbB ligands...
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactionsI Alroy
Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel
FEBS Lett 410:83-6. 1997..The resulting signaling network has important implications for embryonic development and malignant transformation...
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteinsG Levkowitz
Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel
Oncogene 12:1117-25. 1996..These results indicate that different ErbB proteins can couple to distinct signaling pathways, and therefore their physiological functions are probably non-redundant...
Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factorI Alroy
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
Mol Cell Biol 19:1961-72. 1999..Moreover, Sp1 seems to act downstream of all members of the ErbB family and thus may funnel the signaling of the ErbB network into the nucleus...
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal fillingC R Pradeep
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncogene 31:907-17. 2012..Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS...
Steel factor and c-kit protooncogene: genetic lessons in signal transductionS Lev
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Crit Rev Oncog 5:141-68. 1994..Predictably, the lessons learned with Kit and Sl mice will be widely relevant to other pairs of ligands and receptors that control the function of different cell lineages and physiological processes...
The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptorH Waterman
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
J Biol Chem 274:22151-4. 1999..Our results attribute to the RING finger of c-Cbl a causative role in endocytic sorting of EGFR and desensitization of signal transduction...
Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat liversY R Hadari
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
J Biol Chem 267:17483-6. 1992..The recruitment of the holoenzyme may also involve its enzymatic activation and thus constitute an important step in the transduction of insulin signals...
The basic biology of HER2I Rubin
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Ann Oncol 12:S3-8. 2001..The recombinant human anti-HER2 monoclonal antibody (rhuMAb-HER2, trastuzumab, Herceptin) induces rapid removal of HER2 from the cell surface, thereby reducing its availability to heterodimers and reducing oncogenicity...
PCR-based identification of new receptors: molecular cloning of a receptor for fibroblast growth factorsV Raz
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Oncogene 6:753-60. 1991..We therefore expect that the methodology we developed will enable the study of new receptors in hardly accessible biological systems such as early mammalian embryos or stem cells...
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptorG Levkowitz
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
Genes Dev 12:3663-74. 1998..These results reveal an endosomal sorting machinery capable of controlling the fate, and, hence, signaling potency, of growth factor receptors...
The murine vik gene (chromosome 9) encodes a putative receptor with unique protein kinase motifsZ Kelman
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Oncogene 8:37-44. 1993..The unique structural landmarks of vik at both the extracellular and the cytoplasmic domains suggest novel ligand as well as substrate specificity of the presumed receptor...
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinasesH Waterman
Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
FEBS Lett 490:142-52. 2001..The involvement of other molecules is reviewed and recent observations that challenge the negative regulatory role of endocytosis are described. Finally, we discuss the relevance of receptor down regulation to cancer therapy...
EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanismG Pines
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncogene 29:5850-60. 2010..This information, along with remarkable sensitivities to tyrosine kinase blockers and to a chaperone inhibitor, proposes strategies for pharmacological interception in brain tumors harboring EGFRvIV mutations...
Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activationE Peles
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
J Biol Chem 267:12266-74. 1992..Hence, we concluded that phosphatidylinositol 3'-kinase is a physiological substrate of the Neu receptor, but the regulation of this coupling is released upon oncogenic activation...
Developmental expression of two murine fibroblast growth factor receptors, flg and bekA Orr-Urtreger
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Development 113:1419-34. 1991..The role of bek and flg in gastrulation and in epithelial-mesenchymal interactions of organogenesis will be discussed...
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptakeE Hurwitz
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Proc Natl Acad Sci U S A 92:3353-7. 1995..These conclusions are relevant to the selection of optimal mAbs for immunotherapy and may have implications for the mechanism of cellular transformation by an overexpressed erbB-2 gene...
A recombinant ectodomain of the receptor for the stem cell factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responsesS Lev
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
J Biol Chem 267:10866-73. 1992..These results indicate that the recombinant ectodomain of the Kit-SCF receptor can be used as a specific antagonist of SCF actions and may enable detailed molecular analysis of ligand-receptor interactions...
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligandsE Tzahar
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Biochim Biophys Acta 1377:M25-37. 1998..This effect, in turn, may promote the growth of carcinoma cells...
Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growthA Emde
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Oncogene 30:1631-42. 2011..Hence, combining mAbs offers a therapeutic strategy, potentially able to enhance clinical efficacy of existing antireceptor immunotherapeutics...
Flg-2, a new member of the family of fibroblast growth factor receptorsA Avivi
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Oncogene 6:1089-92. 1991..Analysis of mRNA from various tissues shows that flg-2 is expressed predominantly in skin, brain and lung...
Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively activeY Yarden
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Proc Natl Acad Sci U S A 87:2569-73. 1990..This mechanism is deregulated in the oncogenic mutant, which is functionally equivalent to ligand-stimulated receptor...
Receptor tyrosine kinases: the emerging tip of systems controlR Seger
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
IET Syst Biol 2:1-4. 2008..As highlighted below, systems control (a layered web of regulatory loops summarised in Fig.1) emerged throughout the workshop as a common theme of many presentations...
[Basic principles of signal transduction]Yosef Yarden
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Onkologie 28:14-7. 2005
Cancer therapeutic antibodies come of age: targeting minimal residual diseaseTsipi Ben Kasus
Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
Mol Oncol 1:42-54. 2007..Here we discuss molecular mechanisms of antibody-based therapy, the emerging ability to target minimal disease and the therapeutic potential of combining antibodies with other modalities...
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological interventionAmi Citri
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Cell Cycle 3:51-60. 2004..Hence, the dependence of ErbB-2 upon Hsp90 reveals an Achilles heel, which opens a window of opportunity for combating cancers driven by the ErbB/HER signaling network...
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cellsE Peles
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
Cell 69:205-16. 1992..We propose the name Neu differentiation factor (NDF) for p44...
Oncogenic growth factor receptors: implications for signal transduction therapyYaron Mosesson
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
Semin Cancer Biol 14:262-70. 2004..The underlying mechanisms are critically examined, with an emphasis on potential drug combinations, which hold promise for enhanced clinical efficacy...
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosisTsipi Ben-Kasus
Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
Proc Natl Acad Sci U S A 106:3294-9. 2009..One potential mechanism, namely the ability of mAb combinations to instigate ErbB-2 endocytosis, is demonstrated. Translation of these lessons to clinical applications may enhance patient response and delay acquisition of resistance...
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migrationMenachem Katz
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
Nat Cell Biol 9:961-9. 2007..In conclusion, a transcriptional tensin-3-cten switch may contribute to the metastasis of mammary cancer...
Signal transduction and oncogenesis by ErbB/HER receptorsMina D Marmor
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
Int J Radiat Oncol Biol Phys 58:903-13. 2004....
Kinase-mediated quasi-dimers of EGFRErez M Bublil
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
FASEB J 24:4744-55. 2010..On the basis of these observations, we propose that quasi-dimers precede formation of ligand-induced, fully active dimers, which are stabilized by both extracellular and intracellular receptor-receptor interactions...
Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7Maya Shelly
Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
Dev Cell 5:475-86. 2003..Hence, distinct domains of Lin-7 regulate receptor delivery to and maintenance at the basolateral surface of epithelia...
The deaf and the dumb: the biology of ErbB-2 and ErbB-3Ami Citri
Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
Exp Cell Res 284:54-65. 2003..This review highlights recent structural insights into the mechanism of ligand-induced heterodimer formation, and concentrates on signaling pathways employed by ErbB-2 and ErbB-3 in normal and in malignant cells...
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formationAmi Citri
Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
EMBO Rep 5:1165-70. 2004..These results define a role for Hsp90 as a molecular switch regulating the ErbB signalling network by limiting formation of ErbB-2-centred receptor complexes...
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligandsMoshit Lindzen
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
Proc Natl Acad Sci U S A 107:12559-63. 2010....
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factorsRoi Avraham
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Sci Signal 3:ra43. 2010..These findings identify specific microRNAs as attenuators of growth factor signaling and oncogenesis...
Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapyGur Pines
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
FEBS Lett 584:2699-706. 2010..Deeper understanding of signaling pathways downstream to mutant receptors will likely improve the outcome of current EGFR-targeted therapies, as well as help develop new drugs and combinations...
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicityBose S Kochupurakkal
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
J Biol Chem 280:8503-12. 2005..In conclusion, EPG might represent the last EGF-like growth factor and define a category of low affinity ligands, whose bioactivity differs from the more extensively studied high affinity ligands...
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapyLilach M Friedman
Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
Proc Natl Acad Sci U S A 102:1915-20. 2005..We present a model attributing efficacy of immunotherapy to the size of Ab-receptor lattices formed at the cell surface, which dictates the rate of endocytic clearance and extent of signaling blockade...
Hsp90 recognizes a common surface on client kinasesAmi Citri
Department of Biological Regulation, Weizmann Institute of Science, Rehovot 97100, Israel
J Biol Chem 281:14361-9. 2006..These lessons bear significance to pharmacological attempts to target the chaperone in human pathologies, such as cancer...
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1Barbara Zsebik
Department of Biophysics and Cell Biology, Faculty of Medicine, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
Immunol Lett 104:146-55. 2006....
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapyAlex Starr
Lung and Allergy Institute, Tel Aviv Sourasky Medical Center and Tel Aviv University School of Medicine, Tel Aviv, Israel
Int J Cancer 119:269-74. 2006..The results of the current study provide evidence that ErbB-4 plays a significant role in human lung cancer and may serve as a molecular target for anticancer therapy...
ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapyRami Ben-Yosef
Department of Oncology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Prostate 67:871-80. 2007....
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cellsNeil L Spector
Duke Comprehensive Cancer Center, Duke University Medical Center, Medical Science Research Building II, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 104:10607-12. 2007....
Research Grants
- Next generation strategies to intercept ErbB signalingYosef Yarden; Fiscal Year: 2006..abstract_text> ..
- ERBB 2 ERBB 3 HETERODIMERIC RECEPTOR OF CARCINOMASYosef Yarden; Fiscal Year: 2004..This model will be examined by using mutant receptors, and the recycling machinery characterized in details. The suspected cancer-inhibitory activity of drugs interfering with ErbB routing will be tested in vivo. ..
- LATERAL VERSUS VERTICAL SIGNALING BY ERBB2 ONCOPROTEINYosef Yarden; Fiscal Year: 1999....
